Compounds > 2-chloro-6-(2-furyl)-9-(4-methoxyphenylmethyl)-9h-purine
Page last updated: 2024-12-10

2-chloro-6-(2-furyl)-9-(4-methoxyphenylmethyl)-9h-purine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-chloro-6-(2-furyl)-9-(4-methoxyphenylmethyl)-9H-purine: has antitubercular activity; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5270751
CHEMBL ID364019
SCHEMBL ID5451814
MeSH IDM0484333

Synonyms (14)

Synonym
2-chloro-6-(2-furyl)-9-[(4-methoxyphenyl)methyl]purine
9h-purine, 2-chloro-6-(2-furanyl)-9-[(4-methoxyphenyl)methyl]-
CHEMBL364019
2-chloro-6-(furan-2-yl)-9-[(4-methoxyphenyl)methyl]purine
SCHEMBL5451814
2-chloro-6-(2-furyl)-9-(4-methoxyphenylmethyl)-9h-purine
SJKOQMCAHSJMCS-UHFFFAOYSA-N
2-chloro-6-(2-furyl)-9-(4-methoxy-phenylmethyl)-9h-purine
mmv687170
AKOS034159032
sr-05000022612
SR-05000022612-1
PD061443
Z3137022201
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (26)

Assay IDTitleYearJournalArticle
AID515914Antibacterial activity against multidrug-resistant Mycobacterium tuberculosis H37Rv carrying luxAB at 128 uM incubated for 10 days under low oxygen followed by 28 hrs normoxic recovery by low-oxygen-recovery assay relative to control2010Bioorganic & medicinal chemistry, Oct-15, Volume: 18, Issue:20
Synthesis of non-purine analogs of 6-aryl-9-benzylpurines, and their antimycobacterial activities. Compounds modified in the imidazole ring.
AID515918Antibacterial activity against isoniazid-resistant Mycobacterium tuberculosis after 7 days by microplate alamar blue assay2010Bioorganic & medicinal chemistry, Oct-15, Volume: 18, Issue:20
Synthesis of non-purine analogs of 6-aryl-9-benzylpurines, and their antimycobacterial activities. Compounds modified in the imidazole ring.
AID244936Minimum inhibitory concentration against Mycobacterium tuberculosis H37Rv2005Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7
Synthesis, biological activity, and SAR of antimycobacterial 9-aryl-, 9-arylsulfonyl-, and 9-benzyl-6-(2-furyl)purines.
AID455072Antimicrobial activity against Mycobacterium tuberculosis H37Rv in african green monkey Vero cells by microplate alamar blue assay2009Bioorganic & medicinal chemistry, Sep-15, Volume: 17, Issue:18
Synthesis, structure, and antimycobacterial activity of 6-[1(3H)-isobenzofuranylidenemethyl]purines and analogs.
AID515924Antibacterial activity against Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry, Oct-15, Volume: 18, Issue:20
Synthesis of non-purine analogs of 6-aryl-9-benzylpurines, and their antimycobacterial activities. Compounds modified in the imidazole ring.
AID309431Antimicrobial activity against Escherichia coli ATCC 259222007Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22
Synthesis, biological activity, and SAR of antimycobacterial 2- and 8-substituted 6-(2-furyl)-9-(p-methoxybenzyl)purines.
AID309430Antimicrobial activity against Staphylococcus aureus ATCC 259232007Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22
Synthesis, biological activity, and SAR of antimycobacterial 2- and 8-substituted 6-(2-furyl)-9-(p-methoxybenzyl)purines.
AID515912Antibacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 after 7 days by microplate alamar blue assay2010Bioorganic & medicinal chemistry, Oct-15, Volume: 18, Issue:20
Synthesis of non-purine analogs of 6-aryl-9-benzylpurines, and their antimycobacterial activities. Compounds modified in the imidazole ring.
AID252942Selectivity index (IC50:MIC) of the compound2005Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7
Synthesis, biological activity, and SAR of antimycobacterial 9-aryl-, 9-arylsulfonyl-, and 9-benzyl-6-(2-furyl)purines.
AID515916Selectivity index, ratio of EC50 for african green monkey Vero cells to MIC for Mycobacterium tuberculosis H37Rv ATCC 272942010Bioorganic & medicinal chemistry, Oct-15, Volume: 18, Issue:20
Synthesis of non-purine analogs of 6-aryl-9-benzylpurines, and their antimycobacterial activities. Compounds modified in the imidazole ring.
AID486159Antimycobacterial activity against Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11
Synthesis and biological evaluation of pyrimidine analogs of antimycobacterial purines.
AID515915Cytotoxicity against african green monkey Vero cells2010Bioorganic & medicinal chemistry, Oct-15, Volume: 18, Issue:20
Synthesis of non-purine analogs of 6-aryl-9-benzylpurines, and their antimycobacterial activities. Compounds modified in the imidazole ring.
AID244892Minimum inhibitory concentration against Mycobacterium avium complex2005Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7
Synthesis, biological activity, and SAR of antimycobacterial 9-aryl-, 9-arylsulfonyl-, and 9-benzyl-6-(2-furyl)purines.
AID515921Antibacterial activity against clofazimine-resistant Mycobacterium tuberculosis after 7 days by microplate alamar blue assay2010Bioorganic & medicinal chemistry, Oct-15, Volume: 18, Issue:20
Synthesis of non-purine analogs of 6-aryl-9-benzylpurines, and their antimycobacterial activities. Compounds modified in the imidazole ring.
AID309433Selectivity index, ratio of IC50 for Vero cells to MIC of Mycobacterium tuberculosis H37Rv2007Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22
Synthesis, biological activity, and SAR of antimycobacterial 2- and 8-substituted 6-(2-furyl)-9-(p-methoxybenzyl)purines.
AID251153Ratio of effective concentration for 90% reduction in mycobacterial growth and minimum inhibitory concentration against Mycobacterium tuberculosis2005Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7
Synthesis, biological activity, and SAR of antimycobacterial 9-aryl-, 9-arylsulfonyl-, and 9-benzyl-6-(2-furyl)purines.
AID455073Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay2009Bioorganic & medicinal chemistry, Sep-15, Volume: 17, Issue:18
Synthesis, structure, and antimycobacterial activity of 6-[1(3H)-isobenzofuranylidenemethyl]purines and analogs.
AID515919Antibacterial activity against streptomycin-resistant Mycobacterium tuberculosis after 7 days by microplate alamar blue assay2010Bioorganic & medicinal chemistry, Oct-15, Volume: 18, Issue:20
Synthesis of non-purine analogs of 6-aryl-9-benzylpurines, and their antimycobacterial activities. Compounds modified in the imidazole ring.
AID610801Antimycobacterial activity against Mycobacterium tuberculosis H37Rv after 4 days by MABA assay2011Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11
Synthesis and antimycobacterial activities of non-purine analogs of 6-aryl-9-benzylpurines: Imidazopyridines, pyrrolopyridines, benzimidazoles, and indoles.
AID515920Antibacterial activity against kanamycin-resistant Mycobacterium tuberculosis after 7 days by microplate alamar blue assay2010Bioorganic & medicinal chemistry, Oct-15, Volume: 18, Issue:20
Synthesis of non-purine analogs of 6-aryl-9-benzylpurines, and their antimycobacterial activities. Compounds modified in the imidazole ring.
AID251736Tested for the inhibition of Mycobacterium tuberculosis growth at a dose of 6.25 ug/mL2005Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7
Synthesis, biological activity, and SAR of antimycobacterial 9-aryl-, 9-arylsulfonyl-, and 9-benzyl-6-(2-furyl)purines.
AID515913Antibacterial activity against multidrug-resistant Mycobacterium tuberculosis H37Rv carrying luxAB incubated for 10 days under low oxygen followed by 28 hrs normoxic recovery by low-oxygen-recovery assay2010Bioorganic & medicinal chemistry, Oct-15, Volume: 18, Issue:20
Synthesis of non-purine analogs of 6-aryl-9-benzylpurines, and their antimycobacterial activities. Compounds modified in the imidazole ring.
AID246805Concentration effecting 99% reduction in mycobacterial growth in Mycobacterium tuberculosis affected Macrophage model after 7 days2005Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7
Synthesis, biological activity, and SAR of antimycobacterial 9-aryl-, 9-arylsulfonyl-, and 9-benzyl-6-(2-furyl)purines.
AID515917Antibacterial activity against rifampicin-resistant Mycobacterium tuberculosis after 7 days by microplate alamar blue assay2010Bioorganic & medicinal chemistry, Oct-15, Volume: 18, Issue:20
Synthesis of non-purine analogs of 6-aryl-9-benzylpurines, and their antimycobacterial activities. Compounds modified in the imidazole ring.
AID246793Concentration effecting 90% reduction in mycobacterial growth in Mycobacterium tuberculosis affected Macrophage model after 7 days2005Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7
Synthesis, biological activity, and SAR of antimycobacterial 9-aryl-, 9-arylsulfonyl-, and 9-benzyl-6-(2-furyl)purines.
AID247556Inhibitory concentration against cytotoxicity in VERO cell line2005Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7
Synthesis, biological activity, and SAR of antimycobacterial 9-aryl-, 9-arylsulfonyl-, and 9-benzyl-6-(2-furyl)purines.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (57.14)29.6817
2010's3 (42.86)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.19

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.19 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.27 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.19)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
isoniazid
Hydra: A genus of freshwater polyps in the family Hydridae, order Hydroida, class HYDROZOA. They are of special interest because of their complex organization and because their adult organization corresponds roughly to the gastrula of higher animals.. hydrazide : Compounds derived from oxoacids RkE(=O)l(OH)m (l =/= 0) by replacing -OH by -NRNR2 (R groups are commonly H). (IUPAC).		2.4620carbohydrazideantitubercular agent;
drug allergen
benzethonium chloride
benzethonium chloride : A (synthetic) quaternary ammonium salt that is benzyldimethylamine in which the nitrogen is quaternised by a 2-{2-[p-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy}ethyl group, with chloride as the counter-ion. An antiseptic and disinfectant, it is active against a broad spectrum of bacteria, fungi, moulds and viruses.		2.0610aromatic ether;
chloride salt;
quaternary ammonium salt		antibacterial agent;
antifungal agent;
antiseptic drug;
antiviral agent;
disinfectant
streptomycin
[no description available]		2.0510antibiotic antifungal drug;
antibiotic fungicide;
streptomycins		antibacterial drug;
antifungal agrochemical;
antimicrobial agent;
antimicrobial drug;
bacterial metabolite;
protein synthesis inhibitor
moxifloxacin
Moxifloxacin: A fluoroquinolone that acts as an inhibitor of DNA TOPOISOMERASE II and is used as a broad-spectrum antibacterial agent.. moxifloxacin : A quinolone that consists of 4-oxo-1,4-dihydroquinoline-3-carboxylic acid bearing a cyclopropyl substituent at position 1, a fluoro substitiuent at position 6, a (4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl group at position 7 and a methoxy substituent at position 8. A member of the fluoroquinolone class of antibacterial agents.		2.0510aromatic ether;
cyclopropanes;
fluoroquinolone antibiotic;
pyrrolidinopiperidine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone		antibacterial drug
pa 824
pretomanid: nitroimidazopyran derived from 5-nitroimidazoles; a prodrug that requires activation by a bacterial F420-depedent glucose-6-phosphate dehydrogenase (Fgd) and nitroreductase to activate components that then inhibit bacterial mycolic acid and protein synthesis; structure in first source		2.4620
2-methyladenosine
2-methyladenosine : A methyladenosine in which the methyl group is located at position 2 on the adenine ring.		2.0210methyladenosine
9-benzyl-2-chloro-6-(2-furyl)purine
9-benzyl-2-chloro-6-(2-furyl)purine: structure in first source		2.4420
rifampin
Rifampin: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)		2.4620cyclic ketal;
hydrazone;
N-iminopiperazine;
N-methylpiperazine;
rifamycins;
semisynthetic derivative;
zwitterion		angiogenesis inhibitor;
antiamoebic agent;
antineoplastic agent;
antitubercular agent;
DNA synthesis inhibitor;
EC 2.7.7.6 (RNA polymerase) inhibitor;
Escherichia coli metabolite;
geroprotector;
leprostatic drug;
neuroprotective agent;
pregnane X receptor agonist;
protein synthesis inhibitor
ConditionIndicatedRelationship StrengthStudiesTrials
Koch's Disease
[description not available]		02.0510
Tuberculosis
Any of the infectious diseases of man and other animals caused by species of MYCOBACTERIUM TUBERCULOSIS.		02.0510